NASDAQ$BBIO
Bridgebio Pharma Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported first quarter 2024 financial results and provided a business update.
BridgeBio Pharma reported a strong financial position after securing up to $1.5 billion in a Q1 2024 capital campaign and launching BridgeBio Oncology Therapeutics (BBOT) with a $200 million private financing. The company is preparing for the potential launch of acoramidis in the US and anticipates three Phase 3 readouts in 2025. Revenue for the quarter was $211.1 million, primarily due to upfront payments from licensing agreements.
- Presented cardiac magnetic resonance imaging evidence consistent with clinical improvement in ATTR-CM patients in the ATTRibute-CM Phase 3 study of acoramidis.
- Believes there is potential to pursue Accelerated Approval for BBP-418 based on recent interactions with the FDA.
- Secured up to $1.5 billion in Q1 2024 through licensing agreements, royalty financing, credit facility refinancing, and stock sales.
- Launched BridgeBio Oncology Therapeutics (BBOT) with a $200 million private financing to accelerate the development of its novel precision oncology pipeline.
Headline financials
Revenue & EPS history
Bridgebio · Revenue · Quarterly
$211M
Revenue by segment
Bridgebio · $100K total across 1 segment · Q2 2023
- License and Services Revenue$100K—100.0%
Forward guidance
BridgeBio is in a strong financial position to launch acoramidis in the US at the end of this year and deliver three Phase 3 readouts in 2025.
Tailwinds
- Potential commercial launch of acoramidis.
- Continued advancement in the company’s pipeline.
- Enrollments in clinical trials and anticipated readouts.
- Benefits resulting from recent financing activities.
- Advancing oncology pipeline into the clinic.
Headwinds
- Initial and ongoing data from the company’s preclinical studies and clinical trials not being indicative of final data.
- Potential size of the target patient populations the company’s product candidates are designed to treat not being as large as anticipated.
- The design and success of ongoing and planned clinical trials.
- Future regulatory filings, approvals and/or sales.
- The impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Gaza Strip, increasing rates of inflation and rising interest rates, on business operations and expectations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.5%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.3%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+40.9%
Q2 2022
Best reaction
-21.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | -3.2% | -0.7% | |
| Q4 2025 | -2.8% | -4.1% | +2.0% | |
| Q3 2025 | -4.9% | -7.9% | +8.1% | |
| Q1 2025 | +5.3% | +4.9% | -6.0% | |
| Q4 2024 | +1.4% | -5.3% | -4.2% | |
| Q3 2024 | -5.1% | -9.2% | +5.9% | |
| Q2 2024 | +0.9% | -4.2% | +7.3% | |
| Q1 2024 | +3.0% | +2.8% | +3.6% | |
| Q4 2023 | -0.5% | +4.6% | -13.4% | |
| Q3 2023 | +8.2% | +10.3% | +16.1% | |
| Q2 2023 | -2.3% | +0.8% | -4.4% | |
| Q1 2023 | -5.0% | -4.4% | -1.0% | |
| Q4 2022 | -4.7% | -6.6% | +21.8% | |
| Q3 2022 | -1.1% | -7.0% | -4.8% | |
| Q2 2022 | +40.9% | +39.7% | +26.7% | |
| Q1 2022 | -21.9% | -29.5% | -15.9% | |
| Q4 2021 | +7.6% | +13.9% | +41.1% | |
| Q3 2021 | +6.8% | +2.0% | -22.8% | |
| Q2 2021 | +2.4% | -1.1% | -2.3% | |
| Q1 2021 | -9.3% | -7.2% | +9.5% | |
| Q4 2020 | +4.9% | -1.8% | -9.8% | |
| Q3 2020 | -1.6% | +0.3% | +30.4% | |
| Q2 2020 | +1.4% | +0.2% | +16.2% | |
| Q1 2020 | -6.8% | +6.1% | -12.7% | |
| Q4 2019 | +2.2% | -9.3% | -21.3% | |
| Q3 2019 | +22.1% | +26.2% | +49.0% | |
| Q2 2019 | +0.0% | +4.8% | -3.2% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro